World Journal of Pharmaceutical
and Medical Research

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 6.842

ICV : 78.6

World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

Abstract

OVARIAN CARCINOSARCOMA: ABOUT A CASE AND REVIEW OF LITERATURE

*Meriem Nadi, Hanane Ouhame, Charaf Fourati, Mounia Malki Yousfi and Samir Bargach

ABSTRACT

Ovarian carcinosarcoma is one of the rarest histological subtypes of ovarian cancer. There are approximately 1-4% of all ovarian cancers. Given the rarity of this histological type, management is often extrapolated from the experience of ovarian adenocarcinoma. The prognosis seems to be more dismal than adenocarcinomas, with a median survival of less than 18 months, very variable according to the studies and the stages of the disease. The histological, homologous or heterologous subtype is not associated with a change in prognosis. On the other hand, the stage of the disease at diagnosis, the age of the patient, the complete surgery, seem to affect survival. Response rate to chemotherapy is approximately 20%. We report a case of 73-year-old female patient, with an ovarian carcinosarcoma stage IIIC.

[Full Text Article]    [Download Certificate]

Powered By WJPMR | All Right Reserved

WJPMR